Halozyme Therapeutics | Sustainability Performance
Biotechnology company developing oncology therapies and drug delivery technologies
1998
United States
201 - 500 employees
Biotechnology
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5423
Overallⓘ#1246
in United Statesⓘ#123
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Halozyme Therapeutics Inc, US drug delivery technology, has faced multiple US class actions over alleged inadequate disclosure of Roche/Janssen/argenx licensee customer concentration risks affecting Halozyme's royalty stream, plus periodic SEC enforcement scrutiny on alleged inadequate disclosure of competitive market displacement affecting institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.